The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.
(Bloomberg) -- The Centers for Disease Control and Prevention is investigating whether the US stockpile of bird flu vaccines is still well matched to the virus after discovering recent mutations. Most Read from BloombergDubai’s Allure to Expats Is Weighing on City’s InfrastructureThe Master Plan That Shaped Pakistan’s Capital Is No Longer WorkingThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsAs Brussels Booms, an Old Boogeyman Returns: BrusselizationChicago Marathon to Hono
Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?